US institution changes share price target for three big Danish drugmakers

Three of Denmark’s biggest life science firms, Novo Nordisk, Lundbeck and Genmab, have had their share price target adjusted by a private wealth manager in the US.

Photo: Jens Dresling

US-based private wealth manager Bernstein has taken stock of three large Danish drugmakers – Novo Nordisk, Lundbeck and Genmab – resulting in share price target changes for all three, Bloomberg News reports.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs